FDA Lifts All Clinical Holds on Seladelpar
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- Wall St rises on AI gains as oil slides, Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips briefly below $100 on Saudi exports, hopes of US-Iran diplomacy
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Qatar Investment Authority targets $20B partnership with JPMorgan - Bloomberg
- AMD stock jumps as chip rally builds ahead of summit
Cantor Fitzgerald Said 'Just the Beginning' of CymaBay Therapeutic (CBAY) Share Recovery After FDA Hold Lifted
July 23, 2020 10:35 AM EDTCantor Fitzgerald analyst Eliana Merle reiterated an Overweight rating and $15.00 price target on CymaBay Therapeutic (NASDAQ: CBAY) after the clinical hold on seladelpar was lifted. The analyst thinks this is just the beginning of a major recovery for shares.
Merle commented, "This morning CBAY announced the FDA lifted the clinical hold on seladelpar across all indications (PBC, PSC, NASH). This is a... More
